OVUM highlights the potential of AI in revolutionizing IVF

Fol­low­ing quick­ly on the heels of US biosim­i­lar ap­provals, Am­s­ter­dam-based Pol­phar­ma Bi­o­log­ics scored a Eu­ro­pean Com­mis­sion au­tho­riza­tion for its Tysabri (na­tal­izum­ab) biosim­i­lar for mul­ti­ple scle­ro­sis,

Share this article The report also covers products from therapy areas such as Oncology, Respiratory, and Dermatology which include the indications Solid Tumor, Ovarian Cancer,

PHILADELPHIA — Artificial intelligence (AI) has an image problem when it comes to healthcare, but it actually represents a big opportunity to improve things, Tom